Michael L Maitland
Affiliation: University of Chicago
- Estimation of renal cell carcinoma treatment effects from disease progression modelingM L Maitland
Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
Clin Pharmacol Ther 93:345-51. 2013..1) with 50 patients per arm. Model-based quantitation of treatment effect with computed tomography (CT) imaging offers a scaffold on which to develop new, more efficient, phase II trial end points and analytic strategies for RCC...
- Volumes to learn: advancing therapeutics with innovative computed tomography image data analysisMichael L Maitland
The University of Chicago Medical Center, Chicago, Department of Medicine, Section of Hematology Oncology, Committee on Clinical Pharmacology and Pharmacogenomics, MC2115, 5841 South Maryland Avenue, Chicago, IL 60637, USA
Clin Cancer Res 16:4493-5. 2010..Volumetric measurements, relying on already widely available standard clinical imaging techniques, could shorten the observation intervals needed to identify cohorts of patients sensitive or resistant to treatment...
- Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitorsMichael L Maitland
Department of Medicine, University of Chicago Medical Center, 5841Chicago, IL 60637, USA
J Natl Cancer Inst 102:596-604. 2010..Proper agent selection, dosing, and scheduling of follow-up should enable maintaining VSP inhibition while avoiding the complications associated with excessive or prolonged elevation in BP...
- Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatmentMichael L Maitland
Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
Clin Cancer Res 15:6250-7. 2009..This prospective, single-center, cohort study characterized ambulatory blood pressure monitoring as an early pharmacodynamic biomarker of VEGF signaling pathway inhibition by sorafenib...
- Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancerMichael L Maitland
Section of Hematology Oncology, The Department of Medicine, University of Chicago Medical Center, Chicago, IL 60637, USA
Lung Cancer 54:243-5. 2006..The frequency with which camptothecin-related dyspnea is associated with diffuse alveolar damage might be underestimated and is of special concern in patients with limited pulmonary reserve...
- Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patientsEzra E W Cohen
Departments of Medicine, University of Chicago, Chicago, IL 60637, USA
Clin Cancer Res 18:4785-93. 2012..Nevertheless, sirolimus is readily available, has been well studied in organ transplant patients, and shows efficacy in several preclinical cancer models...
- Resampling phase III data to assess phase II trial designs and endpointsManish R Sharma
Departments of Medicine and Health Studies, University of Chicago, Chicago, Illinois, USA
Clin Cancer Res 18:2309-15. 2012..placebo; TARGET) and a negative (AE941 vs. placebo) phase III trial in metastatic renal cancer to compare the ability of various designs and endpoints to predict the known results...
- Sunitinib, hypertension, and heart failure: a model for kinase inhibitor-mediated cardiotoxicityRajesh Gupta
Division of Cardiology and Feinberg Cardiovascular Research Institute, Northwestern University, 303 East Chicago Avenue, Chicago, IL 60611, USA
Curr Hypertens Rep 13:430-5. 2011..The associated heart failure is less common; it can be reversible but must be actively monitored and managed. Mechanistic insights suggest that an attentive clinical strategy for hypertension could prevent severe cardiotoxicity...
- Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignanciesTara C Gangadhar
Division of Hematology and Oncology, University of Chicago, Chicago, Illinois 60637, USA
Clin Cancer Res 17:1956-63. 2011..Sorafenib and sunitinib are small molecule inhibitors of multiple kinases including VEGF receptor (VEGFR) kinases. These agents have different mechanisms of action, providing a strong rationale for combination...
- Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growthNisha C Kakodkar
Departments of Pediatrics, University of Chicago, Chicago, IL 60637, USA
Pediatr Blood Cancer 59:642-7. 2012..In this study we tested the effects of sorafenib, a multi-kinase inhibitor, on neuroblastoma cell proliferation and signaling, and in mice with subcutaneous human neuroblastoma xenografts or orthotopic adrenal tumors...
- Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitorsKelly L Snider
Section of Hematology Oncology, University of Chicago, Chicago, IL 60637, USA
Target Oncol 4:67-76. 2009..In addition to reviewing current concepts for the cardiovascular toxicities of angiogenesis inhibitors, we discuss how better understanding the pharmacologic basis for these effects could optimize their use for individual patients...
- Cancer pharmacogenomics: strategies and challengesHeather E Wheeler
Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, 900 East 57th Street, Chicago, Illinois 60637, USA
Nat Rev Genet 14:23-34. 2013..We discuss the application of germline genetics analysis methods to cancer pharmacogenomics with a focus on the special considerations for study design...
- Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertensionLiliana Moreno-Vinasco
Section of Pulmonary and Critical Care Medicine, Department of Medicine, Pritzker School of Medicine, University of Chicago, Chicago, Illinois 60637, USA
Physiol Genomics 33:278-91. 2008..In summary, sorafenib represents a novel potential treatment for severe PH with the MAPK cascade a potential canonical target...
- Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancerTheodore G Karrison
Department of Health Studies, University of Chicago, Chicago, IL 60637, USA
J Natl Cancer Inst 99:1455-61. 2007..This design may efficiently eliminate truly ineffective therapy but may not reliably indicate whether subsequent phase III testing is warranted...
- Analysis of the yield of phase II combination therapy trials in medical oncologyMichael L Maitland
Section of Hematology Oncology, Department of Medicine, The University of Chicago, Chicago, Illinois 60637, USA
Clin Cancer Res 16:5296-302. 2010..We hypothesized that recognized flaws of single-arm trials could be magnified in combination treatment studies, leading to many reported positive phase II trials but with a low fraction resulting in practice-changing phase III trials...
- Clinical trials in the era of personalized oncologyMichael L Maitland
Section of Hematology Oncology, Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, IL 60637, USA
CA Cancer J Clin 61:365-81. 2011....
- RECIST: No Longer the Sharpest Tool in the Oncology Clinical Trials Toolbox--PointManish R Sharma
Authors Affiliations Department of Medicine, Comprehensive Cancer Center, and Committee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, Illinois
Cancer Res 72:5145-9. 2012..We discuss how the new paradigm overcomes these limitations and provides a framework for answering the key questions of the oncologist and improving patient outcomes. Cancer Res; 72(20); 5145-9. ©2012 AACR...
- Other paradigms: better treatments are identified by better trials: the value of randomized phase II studiesManish R Sharma
Section of Hematology, University of Chicago Medical Center, Chicago, IL, USA
Cancer J 15:426-30. 2009..Finally, we make the case that randomized phase II trials are feasible, as long as reasonable statistical standards are applied...
- TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?Michael L Maitland
Department of Medicine, Committee on Clinical Pharmacology and Pharmacogenomics, and Cancer Research Center, University of Chicago, Chicago, IL 60637, USA
Trends Pharmacol Sci 27:432-7. 2006....
- Interpreting disparate responses to cancer therapy: the role of human population geneticsMichael L Maitland
Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA
J Clin Oncol 24:2151-7. 2006..Understanding these principles will help investigators better design clinical trials to identify the variables most relevant to subsequent individualization of a cancer therapy...
- Inflammation, growth factors, and pulmonary vascular remodelingPaul M Hassoun
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins University, Baltimore, Maryland 21287, USA
J Am Coll Cardiol 54:S10-9. 2009....
- Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancerStephen L Archer
University of Chicago, Section of Cardiology, IL 60637, USA
Am J Physiol Heart Circ Physiol 294:H570-8. 2008..Mitochondrial abnormalities that disturb the ROS-HIF-1alpha-Kv1.5 O(2)-sensing pathway contribute to the pathogenesis of PAH and cancer and constitute promising therapeutic targets...
- Kinase inhibition-related adverse events predicted from in vitro kinome and clinical trial dataXinan Yang
Center for Biomedical Informatics, The University of Chicago, Chicago, IL, USA
J Biomed Inform 43:376-84. 2010..The purpose of this study was to develop a bioinformatics-based method to predict specific adverse events (AEs) in humans associated with the inhibition of particular kinase targets (KTs)...
- Terminal ballistics of kinase inhibitors: there are no magic bulletsMichael L Maitland
Ann Intern Med 145:702-3. 2006
- Translational Medicine and Cancer Therapy with Vasculature-Targeted AgentsMichael Maitland; Fiscal Year: 2007..This "personalized medicine" promises safer, more effective treatment for patients with cancer. This grant will help train Dr. Maitland to be an expert in the conduct of clinical and laboratory studies for personalized cancer medicine. ..